Why the FDA asked for more testing on flibanserin for HSDD

But the panel points to “widespread unmet need” for a medical therapy for HSDD in recommending that the drug maker continue to study the agent

Senior Editor, OBG Management

When the FDA Advisory Committee for Reproductive Health Drugs convened in mid-June to consider approving the nonhormonal agent flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, there was no FDA-approved drug for the disorder.

There still isn’t.